Par’Immune is a biopharmaceutical company founded as the result of a synergy between its co-founders, Prof. Monique Capron and Dr. Abderrahim Lachgar, which technology relies on a parasite- protein as agent of immunoregulation. Par’Immune expertise derives from 20 years of research by Prof Monique Capron and her team at different academic organizations in Lille: a schistosome protein named P28GST has been characterized, cloned and now produced as a highly purified recombinant molecule at GMP grad. Besides its protective role in experimental schistosomiasis, the immunomodulatory potential of P28GST has been extended to preclinical models of several diseases and a Phase 2a clinical trial is ongoing in Crohn’s disease. The cornerstone of Par’Immune is the development of P28GST as immunotherapeutic platform for autoimmune inflammatory diseases such as Crohn’s diseases, ulcerative colitis, and psoriasis. We are developing a First-In-Class Therapeutic approach, and we are building a pharmaceutical company with a strong portfolio: Once the POC in primary indications is achieved, we are planning to perform clinical trials in different inflammatory diseases. Concomitantly, we are working on different formulations and administration routes of our product, and we are planning to initiate collaboration with different partners to evaluate combination of our therapeutic approach with other treatment to increase its efficacy.